Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
919 PLN | +0.77% | +1.66% | -0.65% |
Mar. 23 | NEUCA S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | NEUCA S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.34 times its sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.65% | 1.02B | B- | ||
+14.23% | 69.5B | C+ | ||
+7.11% | 8.2B | B | ||
-20.55% | 7.97B | B- | ||
-4.06% | 7.84B | C | ||
+2.26% | 4.66B | B- | ||
+17.12% | 4.32B | B+ | ||
+1.41% | 4.19B | B- | ||
-3.02% | 3.89B | B | ||
+21.42% | 3.62B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NEU Stock
- Ratings NEUCA S.A.